GRAY supports Evestia Clinical on its acquisition of Emtex Life Science

GRAY Financial Modelling has supported Evestia Clinical, backed by Kester Capital, on its acquisition of Emtex Life Science, building the acquisition and consolidation model for the transaction.
Emtex, based in Belgium, is a specialist in regulatory medical writing and scientific communications with more than 25 years of experience.
Evestia Clinical is a London-based independent global contract research organisation. The deal expands its European footprint and its full-service clinical research offering. It is Evestia's second European acquisition of 2026, following ICRC-Weyer in Germany in January.
GRAY's model was built to evaluate Emtex and to give the group a consistent way to assess further acquisitions as it grows.
Carl Hvass, CFO of Evestia Clinical, said “Joe did a fantastic job supporting us on the Emtex acquisition. His financial modelling was first class, technically strong, commercially focused and gave us real clarity throughout the transaction. Just as importantly, he was incredibly responsive and a pleasure to work with.”




